WO2024208244 - ANTI-IGF1R ANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2024/208244
Publication Date
10.10.2024
International Application No.
PCT/CN2024/085734
International Filing Date
03.04.2024
Title **
[English]
ANTI-IGF1R ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-IGF1R ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD.
Inventors
AN, Wenqian
CAO, Wenpeng
LI, Rifei
WANG, Zilin
Priority Data
PCT/CN2023/086082
04.04.2023
CN
PCT/CN2023/115246
28.08.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3285 | |
| EPO | Filing, Examination, Granting | 39545 | |
| Japan | Filing, Examination, Granting | 3491 | |
| South Korea | Filing, Examination, Granting | 4751 | |
| USA | Filing, Examination, Granting | 20540 |
Total:
71,612
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are anti-IGF1R (insulin-like growth factor 1 receptor) antibodies, antigen-binding fragments,and the uses thereof.[French]
L'invention concerne des anticorps anti-IGF1R (récepteur du facteur de croissance 1 de type insuline), des fragments de liaison à l'antigène et leurs utilisations.